SCYNEXIS announced today, October 16 2025, that it has reached a settlement with GlaxoSmithKline (GSK) regarding the restart of its Phase 3 MARIO study for invasive candidiasis. The agreement provides SCYNEXIS with a $22 million payment from GSK and confirms that no additional milestone payments will be received for the MARIO study.
The settlement also includes a $2.3 million payment to cover wind‑down activities associated with terminating the MARIO study. GSK reiterated its commitment to continue collaboration on the BREXAFEMME NDA transfer and to the commercialization of BREXAFEMME for vulvovaginal candidiasis and recurrent VVC indications.
The $24.3 million total inflow offers a short‑term cash boost amid SCYNEXIS’s ongoing liquidity challenges, while the company remains focused on its broader antifungal pipeline, including the second‑generation SCY‑247 candidate. The resolution effectively ends SCYNEXIS’s pursuit of the MARIO study and clarifies the company’s future partnership with GSK.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.